Dempze Nancy E boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 0.1% during the third quarter, Holdings Channel reports. The institutional investor owned 22,183 shares of the pharmacy operator’s stock after buying an additional 20 shares during the period. CVS Health Corporation comprises approximately 3.5% of Dempze Nancy E’s investment portfolio, making the stock its 5th largest position. Dempze Nancy E’s holdings in CVS Health Corporation were worth $1,974,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the stock. Henderson Group PLC raised its position in shares of CVS Health Corporation by 3.3% in the second quarter. Henderson Group PLC now owns 957,951 shares of the pharmacy operator’s stock valued at $91,709,000 after buying an additional 30,279 shares during the period. Hedeker Wealth LLC boosted its stake in shares of CVS Health Corporation by 20.4% in the second quarter. Hedeker Wealth LLC now owns 22,574 shares of the pharmacy operator’s stock valued at $2,161,000 after buying an additional 3,829 shares in the last quarter. Concert Wealth Management Inc. boosted its stake in shares of CVS Health Corporation by 44.8% in the second quarter. Concert Wealth Management Inc. now owns 12,994 shares of the pharmacy operator’s stock valued at $1,247,000 after buying an additional 4,021 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in shares of CVS Health Corporation during the second quarter valued at about $218,000. Finally, Cypress Capital Management LLC WY acquired a new stake in shares of CVS Health Corporation during the second quarter valued at about $164,000. 81.29% of the stock is owned by hedge funds and other institutional investors.
CVS Health Corporation (NYSE:CVS) opened at 78.53 on Monday. The company has a 50-day moving average of $79.81 and a 200-day moving average of $85.14. The stock has a market capitalization of $83.32 billion, a price-to-earnings ratio of 16.00 and a beta of 0.85. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $106.67.
CVS Health Corporation (NYSE:CVS) last announced its earnings results on Thursday, February 9th. The pharmacy operator reported $1.71 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.04. CVS Health Corporation had a return on equity of 17.55% and a net margin of 3.00%. The company had revenue of $46 billion for the quarter, compared to analyst estimates of $46.56 billion. During the same period in the prior year, the company posted $1.53 EPS. CVS Health Corporation’s quarterly revenue was up 11.7% on a year-over-year basis. Equities research analysts expect that CVS Health Corporation will post $5.86 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, February 2nd. Shareholders of record on Tuesday, January 24th were given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.55%. This is a positive change from CVS Health Corporation’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Friday, January 20th. CVS Health Corporation’s dividend payout ratio is presently 40.65%.
COPYRIGHT VIOLATION NOTICE: “Dempze Nancy E Boosts Position in CVS Health Corporation (CVS)” was first reported by sleekmoney and is owned by of sleekmoney. If you are reading this report on another website, it was illegally copied and republished in violation of international trademark and copyright legislation. The correct version of this report can be read at http://sleekmoney.com/dempze-nancy-e-boosts-position-in-cvs-health-corporation-cvs/1657599.html.
Several brokerages have recently issued reports on CVS. Leerink Swann set a $90.00 price target on shares of CVS Health Corporation and gave the stock a “buy” rating in a research report on Saturday. Evercore ISI reduced their price target on shares of CVS Health Corporation from $91.50 to $84.00 and set a “buy” rating on the stock in a research report on Thursday. Deutsche Bank AG reissued a “hold” rating and set a $88.00 price target on shares of CVS Health Corporation in a research report on Wednesday, February 8th. Atlantic Securities cut shares of CVS Health Corporation from an “overweight” rating to a “neutral” rating and set a $84.00 price target on the stock. in a research report on Monday, February 6th. Finally, Guggenheim reissued a “buy” rating and set a $90.00 price target on shares of CVS Health Corporation in a research report on Monday, February 6th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. CVS Health Corporation presently has an average rating of “Buy” and an average target price of $95.72.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/dempze-nancy-e-boosts-position-in-cvs-health-corporation-cvs/1657599.html
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.